The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Wonder why the technical director left if its all so hunky doorey? Maybe he wasn't happy with all the "gold nuggets" that kept "appearing" all over the place.
There is a reason the MC is so low. Smart people are staying well clear!
People involved stink!
Acquisition of Citiva Jamaica LLC and Collaboration Agreement with University of West Indies
Director Loan Agreement
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK-based international pharmaceutical company trading on the Aquis Stock Exchange, is delighted to announce that its Jamaican affiliate, Apollon Formularies Jamaica Ltd ("Apollon Jamaica"), has reached an agreement to acquire Citiva Jamaica LLC ("Citiva Jamaica") (the "Acquisition") in a part-cash, part-shares transaction.
The Acquisition of Citiva Jamaica, originally started by Josh Stanley, Co-Founder of Charlotte's Web, gives Apollon Jamaica ownership of a world class research, cultivation, manufacturing and processing facility, affiliated with, and located in the Medical School of the University of West Indies ("UWI") campus. The Acquisition delivers on Apollon's previously stated desire to become a vertically integrated, globally recognised medical cannabis business providing treatments and medicines for various human afflictions with a specific focus on cancer.
Transaction Highlights:
• Apollon Jamaica has acquired a university-affiliated, world class research, cultivation, manufacturing, and processing facility for medical grade cannabis
• Citiva Jamaica's facilities give the Company a clear path to large scale manufacturing of high-quality medical grade, full and broad-spectrum oils with GMP certification for use in its patent protected cancer, chronic pain and inflammation treatments, including for international marketing and distribution
• Importantly, Apollon can now achieve the final approval step with the Ministry of Health and Wellness in Jamaica to distribute its patented cannabis based medical products into the Jamaican national pharmacy and dispensary network, the broader Caribbean Community ("CARICOM"), the Southern African Development Community ("SADC") as well as other targeted markets globally
• The Citiva Jamaica facility comes with a Cannabis License Authority (CLA) issued Cultivation Licence, extensive indoor cultivation facilities with cannabis cultivars currently growing and nearing harvest time, approximately 30-35 kg of processed full spectrum medical cannabis oil, and processing equipment
• Under the terms of the arrangement, Apollon Jamaica will acquire a 96% ownership of Citiva Jamaica (in stages), with UWI potentially holding 10% subject to the Company offering them an increase from 4% to 10%
• Expected to create significant revenue growth for the Company over the next 12 months
In consideration for the Acquisition, Apollon will pay US$60,000 cash as well as issue 18,465,910 new Ordinary Shares in Apollon to CJL Holdings, a US based group. The shares will be subject to a nine-month, orderly market, lock-in agreement with one third of the shares becoming unrestricted after each 3-month period from the transaction date. Following compl
100% agree
if all us small peeps vote against their reelection maybe we can get some change ad something done rather then the b@!!$%!t thats been fed to us for the last 2 years.
ive broken my bank here
vote them out... vote them out.... vote them out.!
Released this morning
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange and focused on the treatment of various cancer conditions using its proprietary medical cannabis formulations, is pleased to announce it is advancing an application to join the OTCQB Market ("OTCQB") in the United States. Apollon's Ordinary Shares will continue to trade on the Aquis Stock Exchange under the symbol APOL.
The Company decided to undertake this application for a second trading platform for its shares at the request of several US based investors and believes that cross trading on the OTCQB will provide enhanced investor benefits, including easier access for potential investors in North America, increased trading hours and improved trading liquidity.
Apollon is also pleased to announce that it is exploring other possible up-listing options on local and international exchanges to increase investor access. The Company will maintain its existing AQSE listing, in addition to any additional up-listing it may undertake.
The Company believes that, due to the growth it has seen both in terms of the build out of its facilities and the increase in patient enquiries, moving to a more well-established exchange will provide easier trading access for institutional investors and improve liquidity for all shareholders.
The Company will provide further detail in due course.
As a side note this is the actual working link to your post...
https://www.gov.uk/government/publications/acmd-advice-on-consumer-cannabidiol-cbd-products
Gazzleberry
You are a good example of someone who actually understands very little.
The advice regarding the CBD is for the potential for unprescribed abuse of CBD to make THC related products. Clearly you cant read which is why you are probably invested in CBX. Regarding the handcuffs quip Apollon is fully licensed and treating patients in a regulated environment. Something non of these other "medical cannabis" jokes even come close to.
Each to their own but we will see which one s are still standing in 12 months...
14 June 2021
Apollon Formularies Secures Cancer Treatment Facility in Jamaica
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a fully licensed medical cannabis company with its operations in Jamaica, is pleased to announce that Apollon Formularies Jamaica ("Apollon Jamaica") has signed a long-term lease for its first International Cancer Institute in the Jamaican capital, Kingston. The new facility will specialise in Complementary and Alternative Medical treatments ("CAM"), for cancer patients. These treatments will include Apollon's medical cannabis products.
The new facility will allow Apollon to expand its patient treatment programme for both Jamaican and international medical patients, and at the same time generating additional revenue for the Company. Alongside benefiting Apollon's patients, the expansion with this facility brings the opportunity to gather invaluable patient data on the Company's medical cannabis formulations. Additionally, this new central location provides Apollon with a facility in the country's key medical hub.
Securing this facility follows Apollon's recent announcement, on 18 May 2021, which stated that its medical cannabis formulations in specific combinations were effective in killing nearly 100% of living HER2+ cancer cells in 3D cell culture by direct cytotoxicity. The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon's CLA licensed affiliate, Apollon Jamaica.
Stephen D. Barnhill, M.D., CEO of Apollon, commented, "We are very excited to be opening the Apollon International Cancer institute in Jamaica which will enable us to begin treating cancer patients using Apollon's CAM treatments. This is a milestone for the Company as it is Apollon's first wholly owned facility, treating patients using the Apollon Formularies medical cannabis formulations. Additionally, it gives us a unique opportunity to gather invaluable data to fully determine the efficacy of Apollon's formulations directly on patients.
"It is our unique suite of licenses, along with the fact that licensed medical doctors in Jamaica are permitted to write prescriptions for Apollon medical cannabis products using formulations inclusive of THC, that makes the Company unique amongst its listed peers in Europe."
Mr. Paul Burke, Chairman and CEO of Apollon Jamaica, commented, "We are very proud to be opening this facility and provide Apollon Formularies' medical cannabis treatments to Jamaicans, as well as patients traveling from international locations. To oversee the facility, we are assembling a team of highly qualified licensed Jamaican physicians, who are experienced in treating cancer patients and are fully knowledgeable in quality, complementary and alternative medical care."
save everyone else googling it like I had too.
Full Extract Cannabis Oil (FECO) is an extraction from the flowers of the cannabis plant. This infusion is known as medical cannabis oil. Interestingly, FECO requires the use of ethanol for extraction. This differentiates FECO from standard THC oil and CBD oil extractions. This unique process maintains the complex properties of the cannabis plant.